In vitro activity of Exebacase (CF-301) against clinical Staphylococcus aureus surveillance isolates from the United States, Europe, and Latin America, 2015-2017.
Exebacase
Lysin
Staphylococcus aureus
Surveillance
Journal
Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
03
06
2019
revised:
16
07
2019
accepted:
29
07
2019
pubmed:
31
8
2019
medline:
18
3
2020
entrez:
31
8
2019
Statut:
ppublish
Résumé
Lysins are direct lytic agents which act through enzymatic cell-wall-hydrolysis and represent a potential new class of antimicrobial agents in development to treat antibiotic-resistant bacterial infections. Exebacase (CF-301) is a first-in-class lysin now in clinical development for the treatment of Staphylococcus aureus (S. aureus) bacteremia and infective endocarditis (IE) when used in addition to conventional antibiotics. Exebacase and comparator antibiotics were tested by broth microdilution against a set of 535 clinical MSSA and MRSA isolates collected from 2015 to 2017 throughout the United States, Europe and South America. All S. aureus isolates were inhibited by ≤1 mg/L exebacase (MIC
Identifiants
pubmed: 31466875
pii: S0732-8893(19)30566-8
doi: 10.1016/j.diagmicrobio.2019.114879
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
exebacase
67F0M5CY5Y
Endopeptidases
EC 3.4.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114879Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.